



KERN HEALTH SYSTEMS

Medi-Cal Non-Split – Billable Codes Claims Informational Guide

Medi-Cal Non-Split-Billable Laboratory Codes

Reference List from Medi-Cal 9-4-2025

Appendix A: Medi-Cal Non Split-Billable Codes

The following HCPCS and CPT codes are designated as non split-billable under Medi-Cal policy. These codes must not be billed with modifiers 26, TC, or 99. This appendix serves as a reference for claims staff to ensure proper billing and compliance.

HCPCS Codes Not Split-Billable

HCPCS Code	Description
G0472	Hepatitis C antibody screening, for individuals at high risk and other covered indication(s)
G0499	Hepatitis B screening in non-pregnant, high-risk individual includes hepatitis B surface antigen (HBsAg) followed by a neutralizing confirmatory test for initially reactive results, and antibodies to HBsAg (anti-HBs) and hepatitis B core antigen (anti-HBc)
G0659	Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem), excluding immunoassays and enzymatic methods, performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes



CPT Codes Not Split-Billable

CPT Code	Description
80143	Acetaminophen
80145	Adalimumab
80151	Amiodarone
80161	Carbamazepine-10,11-epoxide
80163	Digoxin; free
80165	Valproic acid (dipropylacetic acid); free
80167	Felbamate
80179	Salicylate
80181	Flecainide
80187	Prosaconazole
80189	Itraconazole
80193	Leflunomide
80204	Methotrexate
80210	Rufinamide
80230	Infliximab
80235	Lacosamide
80280	Vedolizumab
80285	Voriconazole
80305	Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; capable of being read by direct optical observation only includes sample validation when performed, per date of service
80306	Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; read by instrument assisted direct optical observation, includes sample validation when performed, per date of service



80307	Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers, chromatography, and mass spectrometry either with or without chromatography, includes sample validation when performed, per date of service
«80501»	Consultations (Clinical Pathology)
81007	Urinalysis; bacteriuria screen, except by culture or dipstick
81025	Urine pregnancy test, by visual color comparison methods
81050	Volume measurement for timed collection, each
81168	CCND1/IGH (t(11;14)) (e.g., mantle cell lymphoma) translocation analysis, major breakpoint, qualitative and quantitative, if performed
81191	NTRK1 (neurotrophic receptor tyrosine kinase 1) (e.g., solid tumors) translocation analysis
81192	NTRK2 (neurotrophic receptor tyrosine kinase 2) (e.g., solid tumors) translocation analysis
81193	NTRK3 (neurotrophic receptor tyrosine kinase 3) (e.g., solid tumors) translocation analysis
81194	NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (e.g., solid tumors) translocation analysis
81277	Cytogenomic neoplasia (genome-wide) microarray analysis, interrogation of genomic regions for copy number and loss-of-heterozygosity variants for chromosomal abnormalities
81278	IGH@/BCL2 (t(14;18)) (e.g., follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative
81279	JAK2 (Janus kinase 2) (e.g., myeloproliferative disorder) targeted sequence analysis (e.g., exons 12 and 13)
81288	MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (e.g., hereditary non-



	polyposis colorectal cancer, Lynch syndrome) gene analysis; promoter methylation analysis
81338	MPL (MPL proto-oncogene, thrombopoietin receptor) (e.g., myeloproliferative disorder) gene analysis; common variants (e.g., W515A, W515K, W515L, W515R)
81339	MPL (MPL proto-oncogene, thrombopoietin receptor) (e.g., myeloproliferative disorder) gene analysis; sequence analysis, exon 10
81347	SF3B1 (splicing factor [3b] subunit B1) (e.g., myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (e.g., A672T, E622D, L833F, R625C, R625L)
81348	SRSF2 (serine and arginine-rich splicing factor 2) (e.g., myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (e.g., P95H, P95L)
81351	TP53 (tumor protein 53) (e.g., Li-Fraumeni syndrome) gene analysis; full gene sequence
81352	TP53 (tumor protein 53) (e.g., Li-Fraumeni syndrome) gene analysis; targeted sequence analysis (e.g., 4 oncology)
81353	TP53 (tumor protein 53) (e.g., Li-Fraumeni syndrome) gene analysis; known familial variant
81357	U2AF1 (U2 small nuclear RNA auxiliary factor 1) (e.g., myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (e.g., S34F, S34Y, Q157R, Q157P)
81360	ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (e.g., myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (e.g., E65fs, E122fs, R448fs)
81413	Cardiac ion channelopathies; genomic sequence analysis panel, must include sequencing of at least 10 genes, including ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A



- 81414 Cardiac ion channelopathies; duplication/deletion gene analysis panel, must include analysis of at least 2 genes, including KCNH2 and KCNQ1
- 81419 epilepsy genomic sequence analysis panel, must include analyses for ALDH7A1, CACNA1A, CDKL5, CHD2, GABRG2, GRIN2A, KCNQ2, MECP2, PCDH19, POLG, PRRT2, SCN1A, SCN1B, SCN2A, SCN8A, SLC2A1, SLC9A6, STXBP1, SYNGAP1, TCF4, TPP1, TSC1, TSC2, and ZEB2
- 81420 Fetal chromosomal aneuploidy (e.g., trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21
- 81435 Hereditary colon cancer syndromes (e.g., Lynch syndrome, familial adenomatosis polyposis); genomic sequence analysis panel, must include analysis of at least 7 genes, including APC, CHEK2, MLH1, MSH2, MSH6, MUTYH, and PMS2
- 81439 Inherited cardiomyopathy genomic sequence analysis panel, must include sequencing of at least 5 genes, including DSG2, MYBPC3, MYH7, PKP2, and TTN
- 81513 Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for *Atopobium vaginae*, *Gardnerella vaginalis*, and *Lactobacillus* species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis
- 81514 Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers for *Gardnerella vaginalis*, *Atopobium vaginae*, *Megasphaera* type 1, Bacterial Vaginosis Associated Bacteria-2 (BVAB-2), and *Lactobacillus* species (*L. crispatus* and *L. jensenii*), utilizing vaginal-fluid specimens, algorithm reported as a positive or negative for high likelihood of bacterial vaginosis, includes separate detection of *Trichomonas vaginalis* and/or *Candida* species (*C. albicans*, *C. tropicalis*, *C. parapsilosis*, *C.*



	dublinsiensis), Candida glabrata, Candida krusei, when reported
81519	Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin embedded tissue, algorithm reported as recurrence score
81522	Oncology (breast), mRNA, gene expression profiling by RT-PCR of 12 genes (8 content and 4 housekeeping), utilizing formalin-fixed paraffin embedded tissue, algorithm reported as recurrence risk score
81528	Oncology (colorectal) screening, quantitative real-time target and signal amplification of 10 DNA markers (KRAS mutations, promoter methylation of NDRG4 and BMP3) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result Note: CPT code 81528 may be billed with modifier 90
81529	Oncology (cutaneous melanoma), mRNA, gene expression profiling by real-time RT-PCR of 31 genes (28 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk, including likelihood of sentinel lymph node metastasis
81541	Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a disease-specific mortality risk score
81542	Oncology (prostate), mRNA, microarray gene expression profiling of 22 content genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as metastasis risk score
81546	Oncology (thyroid), mRNA, gene expression analysis of 10,196 genes, utilizing fine needle aspirate, algorithm reported as a categorical result (e.g., benign or suspicious)



81552	Oncology (uveal melanoma), mRNA, gene expression profiling by real-time RT-PCR of 15 genes (12 content and 3 housekeeping), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis
81554	Pulmonary disease (idiopathic pulmonary fibrosis [IPF]), mRNA, gene expression analysis of 190 genes, utilizing transbronchial biopsies, diagnostic algorithm reported as categorical result (e.g., positive or negative for high probability of usual interstitial pneumonia [UIP])
82044	Albumin; urine, microalbumin, semiquantitative (e.g., reagent strip assay)
82077	Alcohol (ethanol); any specimen except urine and breath, immunoassay (e.g., IA, EIA, ELISA, RIA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)
«82233	Beta-amyloid; 1-40 (Abeta 40)
82234	Beta-amyloid; 1-42 (Abeta 42)»
82681	Estradiol; free, direct measurement (e.g., equilibrium dialysis)
82962	Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use
83013	Helicobacter pylori; breath test analysis for urease activity, non-radioactive isotope
83014	Helicobacter pylori; drug administration
83876	Myeloperoxidase (MPO)
83951	Oncoprotein; des-gamma-carboxy-prothrombin (DCP)
84410	Testosterone; bioavailable, direct measurement
«84393	Tau, phosphorylated (eg, pTau 181, pTau 217), each
84394	Tau, total (tTau)»



85060	Blood smear, peripheral, interpretation by physician with written report
85097	Bone marrow, smear interpretation
85397	Coagulation and fibrinolysis, functional activity, not otherwise specified, (e.g., ADMTS-13) each analyte
86077	Blood bank physician services; difficult cross match and/or evaluation of irregular antibody(s), interpretation and written report
86078	Blood bank physician services; investigation of transfusion reaction including suspicion of transmissible disease, interpretation and written report
86079	Blood bank physician services; authorization for deviation from standard blood banking procedures (e.g., use of outdated blood, transfusion of Rh incompatible units), with written report
«86485 thru 86581»	Immunology
86930	Frozen blood, each unit; freezing (includes preparation)
86931	Frozen blood, each unit; thawing
86932	Frozen blood, each unit; freezing (includes preparation) and thawing
87483	Infectious agent detection by nucleic acid (DNA or RNA); central nervous system pathogen, includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12 thru 25 targets
87505	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (e.g., Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3 thru 5 targets
87506	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (e.g., Clostridium difficile, E. coli, Salmonella, Shigella, norovirus,



	Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6 thru 11 targets
87507	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (e.g., Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12 thru 25 targets
87563	Infectious agent detection by nucleic acid (DNA or RNA); mycoplasma genitalium, amplified probe technique
«87564	Infectious agent detection by nucleic acid (DNA or RNA); Mycobacterium tuberculosis, rifampin resistance, amplified probe technique
87594	Infectious agent detection by nucleic acid (DNA or RNA); Pneumocystis jirovecii, amplified probe technique»
87624	Human Papillomavirus (HPV), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 56, 58, 59, 68)
87625	Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed
«87626	Detection test by nucleic acid for Human Papillomavirus (HPV), separately reported high-risk types»
87662	Infectious agent detection by nucleic acid (DNA or RNA); Zika virus, amplified probe technique
87806	Infectious agent antigen detection by immunoassay with direct optical observation; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies
87905	Infectious agent enzymatic activity other than virus (e.g., sialidase activity in vaginal fluid)
88141	Cytopathology, cervical or vaginal (any reporting system); requiring interpretation by physician



88184	Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker
88185	Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker
88187	Flow cytometry, interpretation; 2 to 8 markers
88188	Flow cytometry, interpretation; 9 to 15 markers
88189	Flow cytometry, interpretation; 16 or more markers
88291	Cytogenetics and molecular cytogenetics, interpretation and report
88321	Consultation and report on referred slides prepared elsewhere
88720	Bilirubin, total, transcutaneous
89055	Leukocyte assessment, fecal, qualitative or semiquantitative

